The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

Nirogacestat therapy shows sustained benefits, including tumor shrinkage and durable responses, in long-term treatment of ...

SpringWorks Therapeutics has established itself as a promising player in the U.S. Small & Mid Cap Biotechnology sector. The company’s primary focus has been on developing innovative therapies for ...

STAMFORD, Conn. - SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), currently trading at $46.27 with a market capitalization of $3.49 billion, has announced that the European Medicines Agency’s Committee ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a $3.48 billion market cap biopharmaceutical company with impressive gross margins of 93%, announced the results of its annual stockholders’ meeting held ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) ...

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, for the treatment of adult and pediatric patients 2 years ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today ...

Rappta Therapeutics Oy has signed an exclusive global license agreement with Springworks Therapeutics Inc. for RPT-04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) ...